Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day

NEW YORK–(BUSINESS WIRE)– Kadmon Holdings, Inc. (NYSE: KDMN) (“Kadmon” or the “Company”) will
present interim data from its ongoing Phase 2 clinical trial of KD025,
the Company’s lead ROCK2 inhibitor, in previously treated patients with
chronic graft-versus-host disease (“cGVHD”). The data will be presented
at Kadmon’s Research and Development (“R&D”) Day in New York City on
Tuesday, July 11, 2017, from 8:45 a.m. to 11:00 a.m. ET.

The R&D Day will feature presentations by key opinion leaders, including
Bruce Blazar, M.D., Regents Professor in the Department of Pediatrics,
Chief of the Pediatric Blood and Marrow Transplantation Program and Vice
Dean for Clinical Investigation at the School of Medicine at the
University of Minnesota, Minneapolis, MN. Dr. Blazar will share the
findings of his preclinical research on KD025 in cGVHD. Also presenting
is Amandeep Salhotra, M.D., Assistant Professor, Hematology and
Hematopoietic Cell Transplantation at City of Hope, Duarte, CA. Dr.
Salhotra will present interim data from the first cohort (KD025 200 mg
QD) of the ongoing cGVHD trial.

Kadmon’s executive management team, led by Harlan W. Waksal, M.D.,
President and Chief Executive Officer, will provide an update on KD025
as well as the Company’s ROCK inhibitor platform. KD025 is being studied
in three ongoing clinical trials in autoimmune and fibrotic diseases: A
placebo-controlled Phase 2 clinical trial in moderate to severe
psoriasis, an open-label Phase 2 clinical trial in idiopathic pulmonary
fibrosis and an open-label Phase 2 clinical trial in cGVHD.

The R&D Day is intended for institutional investors and sell-side
analysts only. For more information, please email Ellen Tremaine,
Manager, Investor Relations at Kadmon, at ellen.tremaine@kadmon.com.
A live and archived webcast of the event, with slides, will be available
on the Investors section of the Kadmon website at www.kadmon.com.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements
may be preceded by the words “may,” “will,” “should,” “expects,”
“plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. We believe that these factors include, but
are not limited to, (i) the initiation, timing, progress and results of
our preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product candidates
into, and successfully complete, clinical trials; (iii) our reliance on
the success of our product candidates; (iv) the timing or likelihood of
regulatory filings and approvals; (v) our ability to expand our sales
and marketing capabilities; (vi) the commercialization of our product
candidates, if approved; (vii) the pricing and reimbursement of our
product candidates, if approved; (viii) the implementation of our
business model, strategic plans for our business, product candidates and
technology; (ix) the scope of protection we are able to establish and
maintain for intellectual property rights covering our product
candidates and technology; (x) our ability to operate our business
without infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other claims;
(xii) regulatory developments in the United States, Europe and other
jurisdictions; (xiii) estimates of our expenses, future revenues,
capital requirements and our needs for additional financing; (xiv) the
potential benefits of strategic collaboration agreements and our ability
to enter into strategic arrangements; (xv) our ability to maintain and
establish collaborations or obtain additional grant funding; (xvi) the
rate and degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain qualified
employees and key personnel; (xx) our ability to achieve cost savings
and other benefits from our efforts to streamline our operations and to
not harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings with
the U.S. Securities and Exchange Commission (SEC), including the
Company’s Quarterly Report on Form 10-Q filed pursuant to Section 13 of
the Securities Exchange Act of 1934, as amended, with the SEC on May 15,
2017. Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170623005081/en/